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Extracellular fibrinogen-bindingprotein (Efb) fromStaphylo-
coccus aureus inhibits platelet activation, although its mecha-
nismof action has not been established. In this study, we discov-
ered that theN-terminal region of Efb (Efb-N) promotes platelet
binding of fibrinogen and that Efb-N binding to platelets pro-
ceeds via two independent mechanisms: fibrinogen-mediated
and fibrinogen-independent. By proteomic analysis of Efb-in-
teracting proteins within platelets and confirmation by pull-
down assays followedby immunoblotting, we identifiedP-selec-
tin and multimerin-1 as novel Efb interaction partners. The
interactionof bothP-selectin andmultimerin-1withEfb is inde-
pendent of fibrinogen.We focused on Efb interactionwith P-se-
lectin. Excess of P-selectin extracellular domain significantly
impaired Efb binding by activated platelets, suggesting that
P-selectin is themain receptor for Efb on the surface of activated
platelets. Efb-N interaction with P-selectin inhibited P-selectin
binding to its physiological ligand, P-selectin glycoprotein
ligand-1 (PSGL-1), both in cell lysates and in cell-free assays.
Because of the importance of P-selectin-PSGL-1 binding in the
interaction between platelets and leukocytes, we tested human
whole blood and found that Efb abolishes the formationof plate-
let-monocyte and platelet-granulocyte complexes. In summary,
we present evidence that in addition to its documented anti-
thrombotic activity, Efb can play an immunoregulatory role via
inhibition of P-selectin-PSGL-1-dependent formation of plate-
let-leukocyte complexes.
Staphylococcus aureus is responsible for numerous ailments
in both humans and animals, ranging from superficial infec-
tions tomore serious invasive diseases inwhich S. aureus enters
the circulation and establishes infection foci in internal tissues,
for example in the heart and bone marrow, leading to endocar-
ditis and osteomyelitis, respectively (1). This invasive capability
of S. aureus is conferred by bacterial adhesins that bind specif-
ically to components of the host’s plasma and extracellular
matrix, such as fibrinogen and fibronectin (2). S. aureus also
produces and secretes numerous proteins that aid infection
and counter the host immune response, including coagulase
(Coa), extracellular matrix-binding protein (Emp), extracellu-
lar adhesive protein (Eap), staphylococcal complement inhibi-
tor (SCIN), Sbi, chemotaxis inhibitory protein (CHIPS), and
extracellular fibrinogen-binding protein (Efb)3 (3–5). Efb is a
165-amino acid extracellular protein that binds fibrinogen (6)
and platelets (7). Efb comprises a 29-residue N-terminal secre-
tion signal followed by a disordered N-terminal half (Efb-N,
residues 30–104) with two repeated regions (residues 46–67
and 77–98) that are homologous to the five to eight repeats in
S. aureus coagulase (6) and a tri-helical bundle C-terminal
domain (Efb-C, residues 105–165) (8). Efb was originally
reported to have two binding sites for fibrinogen, one located in
Efb-N (9) and the other located in Efb-C (10). Subsequent stud-
ies, however, found that Efb-C is not involved in binding fibrin-
ogen (11, 12) and that there are two fibrinogen binding sites
within Efb-N, each including one of the aforementioned coag-
ulase-like repeats (11). On the other hand, Efb-C seems to play
an immunosuppressive role by interfering with the comple-
ment system (8, 13). Efb and its homologue Ehp (Efb homo-
logous protein, also known as Ecb for extracellular comple-
ment-binding protein) are essential for S. aureus virulence in
vivo (14). In fact, S. aureus infections are significantly exacer-
bated in vivo in the presence of Efb (15, 16), and Efb impairs
wound healing (17). Interestingly, Efb has previously been
shown to inhibit platelet aggregation in vitro (18) and hemosta-
sis in vivo (19). The inhibition of platelet activation and throm-
bus formation by Efb has been suggested to facilitate S. aureus
survival in the blood and to aggravate S. aureus infection (20).
Despite these important observations, the Efb mechanism of
action has not yet been fully characterized. Efb antiplatelet
activity has been suggested to depend on the inhibition of plate-
let-fibrinogen binding by Efb-N (21), but solid experimental
confirmation of this hypothesis remains elusive.
In this study, we first assessedwhich part of Efb is responsible
for Efb antithrombotic activity using recombinant Efb, Efb-N,
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and Efb-C constructs.We then analyzed the effect of these con-
structs on fibrinogen binding of resting and activated platelets
and determined the platelet binding ability of the Efb con-
structs. We then identified novel Efb-binding platelet proteins.
One such protein, P-selectin, which binds Efb directly in the
absence of fibrinogen, mediates platelet-leukocyte complex
formation via its interaction with PSGL-1 (22, 23). We have
shown that Efb inhibits both P-selectin-PSGL-1 binding and
platelet-leukocyte complex formation. Other bacterial pro-
teins, such as S. aureus staphylococcal superantigen-like 5
(SSL5) and staphylococcal enterotoxin-likeX (SEIX), have been
shown to bind PSGL-1 on neutrophils and interfere with the
interaction between PSGL-1 and P-selectin (24, 25).
In summary, we have characterized a novel mechanism of
action of Efb as an inhibitor of platelet-leukocyte complexation
via abolition of P-selectin-PSGL-1 interaction. Because plate-
let-leukocyte complexes play an increasingly recognized role in
the innate immune response (26, 27), this study provides an
additional explanation for the immunosuppressive activity of
Efb.
Experimental Procedures
Expression of Efb Protein Constructs—Recombinant full-
length Efb (residues 29–165, cloned in pET15b), Efb-N (29–
103, pBG100), and Efb-C (101–165, pSV281) were expressed in
BL21(DE3) (Efb and Efb-N) and Arctic Express (DE3)RIL (Efb-
C). The plasmids pBG100 and pSV281 were kindly provided by
the Vanderbilt University Center for Structural Biology.
Expression of Efb and Efb-C was induced overnight at 12 °C,
and expression of Efb-N was induced for 1 h at 37 °C. Proteins
were purified usingNi-affinity chromatography. Fractions con-
taining pure protein were pooled, concentrated to 1 ml, and
dialyzed into a modified Tyrode’s-HEPES buffer (10 mM
HEPES, 145mMNaCl, 2.9 mMKCl, 1 mMMgCl2, 5 mM glucose,
pH 7.3).
Whole Blood, Platelet-rich Plasma (PRP), andWashed Plate-
let Preparation—Human blood was drawn from healthy volun-
teers by median cubital vein venipuncture under local ethics
committee approval. Sodium citrate was used as anticoagulant
(0.5%w/v for platelet isolation, 0.1%w/v for whole blood exper-
iments). PRPwas separated fromwhole blood by centrifugation
(200  g, 15 min), and platelets were separated from PRP by a
second centrifugation step (400 g, 10 min), in the presence of
prostaglandin E1 (PGE1, 40 ng/ml) and indomethacin (10 M).
Washed platelets were then resuspended in a modified
Tyrode’s-HEPES buffer (see above) at a density of 4 108/ml.
Thrombus Formation—The Bioflux200 system (Fluxion,
South San Francisco, CA)was used to analyze thrombus forma-
tion in human whole blood under flow (shear rate 1000 s1).
Microchannels were coated with 0.1 mg/ml collagen I (mono-
meric collagen from calf skin). PRP was isolated from blood by
centrifugation (200  g, 15 min) and incubated for 1 h with
CalceinTM (5 g/ml) at 37 °C to facilitate thrombus visualiza-
tion in whole blood. Labeled platelets were then isolated from
PRP (centrifugation), resuspended in unlabeled plasma, and
FIGURE 1. Efb and Efb-N inhibit whole blood thrombus formation. Plate-
lets in human PRP were labeled by incubation for 1 h with 5 M calcein AM
before reconstitutionofwholeblood.Artificialmicrovesselswere coatedwith
0.1 mg/ml collagen and infused with reconstituted blood at a shear rate of
1000 s1. Thrombus formation was followed by fluorescence microscopy for
10min, in thepresenceof 5MEfb, Efb-N, or Efb-C. In all cases, the controlwas
amicrovessel infusedwithwholebloodwith labeledplatelet plus 5MBSA.A,
theBioflux200apparatus. Amultichannel lid appliespressure toan inputwell,
which in turn feeds blood under physiological shear stress into amicrovessel
mounted on a fluorescencemicroscope. B, the results from five independent
experiments were analyzed and are displayed as means S.E. The statistical
significance of the difference was analyzed by one-way ANOVA with Bonfer-
roni post test (* p 0.05, n 5). Ctrl, control. C, representative examples of
the results with aggregated platelets shown in lighter green.
FIGURE 2.Full-lengthEfbpromotes fibrinogenbindingbyplatelets.Binding
of 50 g/ml FITC-fibrinogen by platelets (107 ml1) in resting conditions or
treatedwith vehicle (5M BSA), 5M Efb, Efb-N, or Efb-C in the presence of 0.25
unit/mlthrombinwasmeasuredbyflowcytometryusingaFACSAria III (n3,*
p0.01byANOVAwithBonferronipost test).A, theforwardscattering(FSC)/side
scattering (SSC) dot plot of the platelet population. B, event histogram for FITC
labelingof resting and thrombin-stimulatedplatelets.R1 is the subpopulationof
plateletswithFITC labeling1000 rfu,which represents 6%5and43%13%
ofthetotalpopulation inrestingandthrombin-stimulatedplatelets, respectively.
C, themean value for FITC-fibrinogen binding for the platelet population is pre-
sentedasmeanS.E. Statistical significancewas testedbyone-wayANOVAwith
Bonferroni post test (* p 0.01, n 4).
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added to the red blood cell fraction to reconstitute whole blood
with physiological blood cell density (including platelets).
Thrombus formation (on collagen) was then visualized by fluo-
rescence microscopy. Representative pictures were taken at
time 10min, and surface area coverage wasmeasured using the
Bioflux200 Software (version 2.4), as described previously (28).
Fluorescent Labeling of Protein and Assessment of Labeled
Protein Binding to Platelets by Flow Cytometry—Fibrinogen or
purified recombinant Efb proteins were labeled with FITC, as
described previously (29). Washed platelets (107 ml1) treated
as indicated for the different experiments were labeled with
FITC-fibrinogen (FITC-FGN, 50 g/ml) or FITC-Efb proteins
(1–3 M). Platelet binding in the presence or absence of 3
mg/ml fibrinogen and 0.25 unit/ml thrombin was assessed by
flow cytometry using a FACSAria III (BD Biosciences, Oxford,
UK).
Proteomics, Pulldown Assays, and Immunoblotting—His-
tagged Efbwas bound to SigmaHis-Select HF nickel affinity gel
by co-incubation for 1 h at 4 °C with mild agitation. Platelet
lysates were obtained by ultrasonication using a Branson 450
Digital Sonifier and incubated with the Efb-bound His-Select
HF resin for 1 h at 4 °Cwithmild agitation, followed bywashing
four times with modified PBS (PBS with 300 mM NaCl and 20
mM imidazole added, pH 8). Efb-interacting platelet proteins
were separated by running the His-Select HF resin on SDS-
PAGE, and subsequently identified bymass spectrometry; pep-
tides from tryptic digestion using a ProGest automated diges-
tion unit (Digilab)were identified using aDionexUltimate 3000
nano-HPLC system in line with an LTQ-Orbitrap Velos mass
spectrometer (Thermo Scientific). Four independent prepara-
tions were used. His-Select HF resin incubated with modified
PBS, without Efb or Efb-N, was used as a negative control. Efb/
Efb-N interactor proteins identified bymass spectrometrywere
confirmed by immunoblotting with specific antibodies and
HRP-linked species-specific secondary antibodies using ECL
detection. The antibodies used were: integrin IIb3 (Millipore
AB1967), fibronectin and thrombospondin-1 (Thermo Scien-
tific (MA5-12314 and MA5-13398, respectively), and multim-
erin-1 and PSGL-1 (Santa Cruz Biotechnology, sc-104427 and
sc-13535, respectively). The P-selectin antibody used for
immunoblotting was Bio-Vision 3633R-100, whereas the P-se-
lectin antibody used for immunoprecipitation was Santa Cruz
Biotechnology sc-6941. The inhibitory antibody for integrin
IIb3 was BioLegend 359804.
P-selectin/Efb Interaction Measured by SPR—P-selectin-Fc
(described under “P-selectin/PSGL-1 Co-immunoprecipita-
tion”) was immobilized on SensiQTM COOHV sensor chips
(SensiQ Technologies, Inc., Oklahoma City, OK) via amine
coupling using 1-ethyl-3-(-3-dimethylaminopropyl) carbodii-
mide hydrochloride (EDC) and N-hydroxysuccinimide (NHS).
SensiQTM COOHV sensor chips contain a high-capacity car-
boxymethyl dextranmatrix. The SPR signal was recorded in the
presence of different concentrations of full-length Efb (100
nM-2.8 M). All experiments were performed using the Sen-
siQTM Pioneer FE SPR platform (SensiQ Technologies). Exper-
imental data were fit using the Qdat data analysis software.
Curves were fitted using a least squares fitting algorithm.
P-selectin/PSGL-1 Co-immunoprecipitation—2 g/ml recom-
binant P-selectin-Fc and PSGL-1-Fc (R&D Systems) were co-
incubated for 2 h in PBS plus 1 mM CaCl2 for the cell-free assay
FIGURE 3. Interaction of the N-terminal region of Efb with platelets. FITC-labeled Efb, Efb-N, Efb-C or BSA (negative control) was incubated at 1 M
concentrationwith humanplatelets (107ml1).Where indicated, the incubationwasperformed in thepresenceof 0.25 unit/ml thrombin (Thr) or 3mg/ml FGN.
Protein bindingwas assessed by flow cytometry using a FACSAria III. A, representative FITC-labeling histograms. R1 is the subpopulation of platelets with FITC
labeling1000 rfu. B, average FITC labeling for different conditions is reportedwith S.E. Statistical significancewas tested by one-way ANOVAwith Bonferroni
post test (* p 0.01 compared with BSA, ** p 0.01 compared with thrombin only for the same protein construct, n 3).
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or platelet lysates were obtained using immunoprecipitation
lysis buffer (150 mM NaCl, 0.5% Nonidet P-40, 10 mM Tris, pH
7.3). The cell-free experiments were performed using P-selec-
tin-Fc and PSGL-1-Fc (recombinant fusion proteins of P-selec-
tin and PSGL-1 with immunoglobulin crystallizable fragments
(Fc)) to allow efficient resuspension of P-selectin and PSGL-1.
This is a common strategy to analyze membrane proteins that
have low hydrophilicity (30, 31). Where indicated, 5 M full-
length Efb or Efb-N was incubated with the protein suspen-
sions/platelet lysates. Either P-selectin or PSGL-1 (10 g/ml)
FIGURE 4. Integrin IIb3 mediates the binding of Efb by platelets in the presence of fibrinogen. FITC-labeled Efb was incubated at 3 M concentration
with human platelets (107 ml1), and binding was assessed by flow cytometry. Representative histograms are shown in A, B, C, and E. Where indicated, the
incubation was performed in the presence of 50g/ml integrin IIb3 inhibitory anti-CD41 antibody (CD41 Ab) (A–D) or 40 ng/ml PGE1 (E and F). Mouse IgG1
 isotype antibodieswere used as negative control in B andC. The experimentswere performed in the presence of 0.25 unit/ml thrombin (Thr) or 3mg/ml FGN,
as indicated in the figures, and performed three times. Protein binding was assessed by flow cytometry using a FACSAria III (n  3). In A, B, C, and E,
representative FITC-labeling histograms are shown with the percentage of events above 1000 rfu (indicated as R1). The data are quantified in D and F, where
the mean fluorescence value S.E. from three independent experiments is reported. Statistical significance was tested by one-way ANOVA with Bonferroni
post test (* p 0.01, n 3). ns non-significant in the pairwise comparison.
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was immunoprecipitated using specific antibodies. Immuno-
precipitated and co-immunoprecipitated proteins were identi-
fied by immunoblotting.
Whole Blood Flow Cytometry and Detection of Platelet-Leu-
kocyte Complexes—Human whole blood samples were incu-
bated with 5 M full-length Efb or Efb-N for 30 min. Red blood
cells were removed using Red Cell Lysis solution (Miltenyi Bio-
tec), and the remaining cells were stained with anti-CD42b,
anti-CD66, and anti-CD38 antibodies for the identification of
platelet-, granulocyte-, and monocyte-specific events respec-
tively. Flow cytometrywas performed using a FACSAria III (BD
Biosciences).
Results
Efb-N Binds Platelets and Exerts Antithrombotic Activity—A
thrombus formation assay in whole human blood under phys-
iological shear stress conditions is a powerful tool to analyze the
hemostatic response and its pro-thrombotic aberrations in
vitro. The antithrombotic activity of Efb has not been tested in
this experimental model. We therefore used a previously
described microfluidics assay (28, 32) to identify the domain of
Efb that inhibits thrombus formation under these conditions.
We used recombinant full-length Efb, Efb-N, and Efb-C. Both
Efb and Efb-N strongly inhibited thrombus formation in whole
human blood in physiological conditions, whereas Efb-C did
not significantly affect thrombus formation (Fig. 1). The throm-
bus formation assay used here models the hydrodynamic con-
ditions and intercellular interactions leading to thrombus for-
mation in the bloodstream and confirms the previously
suggested potential of Efb as an antithrombotic agent (18, 19).
These data strongly suggest that Efb-N binds to platelets and
exerts the antithrombotic activity of Efb.
Efb Binds to Platelets via Both Fibrinogen-dependent and
Fibrinogen-independent Mechanisms—Building on previous
studies that did not provide a complete and definitive picture
on the effect of Efb on fibrinogen binding by platelets and did
not characterize the effect of Efb-N and Efb-C separately (11,
18, 19, 21), we investigated the effect of recombinant Efb,
Efb-N, or Efb-C on washed platelet binding of fibrinogen. As
expected, fibrinogen binding wasminimal in resting conditions
and was significantly increased by platelet stimulation by 0.25
unit/ml thrombin. Surprisingly, Efb and Efb-N mediated an
increase rather than a decrease in fibrinogen binding upon
platelet activation with thrombin (Fig. 2).
We next assessed whether Efb can bind washed platelets
directly. Efb, Efb-N, or Efb-Cwas FITC-labeled andused in flow
cytometry experiments with washed platelets. Both Efb and
Efb-N bound to washed platelets, but only in the presence of
thrombin (0.25 unit/ml) or extracellular fibrinogen (3 mg/ml)
(Fig. 3).
FIGURE 5. Efb interacts with platelet P-selectin. A, human platelets were
ultrasonicated in the presence or absence of 3 mg/ml added fibrinogen.
Sigma His-Select HF nickel affinity gel was used to capture His-tagged Efb- or
Efb-N-interacting proteins from platelet lysates. Affinity precipitates were
separatedby SDS-PAGEand immunoblotted for integrinIIb, P-selectin,mul-
timerin-1, fibronectin, thrombospondin-1 (indicated by Thrombosp.-1), and
His tag (to confirm Efb/Efb-N expression and immobilization). Immunoblots
shownhereare representativeof those fromthree independentexperiments.
-ve, negative control; PD, pulldown. B, SPR data confirm the direct interaction
of Efb and P-selectin. Recombinant P-selectin-Fc immobilized on COOHV-
coated SensiQTM sensor chips was treated with increasing concentrations of
Efb (100nM (brown), 300nM (purple), and2.8M (green)). All experimentswere
performed using the SensiQTM Pioneer FE SPR platform (SensiQ Technolo-
gies). Experimental data were fit using the Qdat data analysis software.
Curves were fitted using a least squares fitting algorithm. RU, response units.
TABLE 1
Platelet proteins interactingwith Efb identifiedbypulldownandmass
spectrometry analysis
SigmaHis-Select HF nickel affinity gel was used to capture His-tagged Efb-interact-
ing proteins from four independent platelet lysates obtained by ultrasonication.
Peptides from tryptic digestion using a ProGest automated digestion unit (Digilab)
were identified using a Dionex Ultimate 3000 nano-HPLC system in line with an
LTQ-Orbitrap Velos mass spectrometer (Thermo Scientific). Four independent
preparations were used for the Efb pulldown, and two independent preparations
were used as a control using HIS-Select beads without Efb (“empty beads”). The
average number of peptide hits for the pulldown samples is reported in the first
numerical column, whereas the average number of hits for the negative controls
(empty beads) is shown in the second numerical column. The ratio between num-
bers of peptides in Efb pulldowns and control pulldowns is shown in the third
column, which quantifies the robustness of the proteomic identification of these
proteins as true interactors of Efb.
Protein name [locus]
Peptide hits
(sample)
Peptide hits
(control) Difference
Known interactors
Plasminogen [PLMN_HUMAN] 243 92 2.64
Complement C3 [CO3_HUMAN] 529 222 2.38
Fibrinogen gamma chain [FIBG_HUMAN] 205 146 1.40
Novel potential interactors
Platelet membrane
P-selectin [Q5R349_HUMAN] 60 27 2.22
Protein unc-13 homolog
D [UN13D_HUMAN]
54 30 1.80
Extracellular/adhesion
Emilin-1 [EMIL1_HUMAN] 62 21 2.95
Multimerin-1 [MMRN1_HUMAN] 77 27 2.85
Fibronectin [B7ZLF0_HUMAN] 133 52 2.56
Thrombospondin-1 [TSP1_HUMAN] 135 86 1.58
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To understand the molecular mechanisms underlying
thrombin- and fibrinogen-dependent binding of Efb to washed
platelets and to assess the role of integrin IIb3, we examined
FITC-Efb binding to platelets by flow cytometry in the presence
of an inhibitory antibody for this integrin. The inhibitory anti-
body for integrin IIb3 only abolished fibrinogen-dependent
binding of Efb, but did not alter the binding of Efb by thrombin-
activated washed platelets (Fig. 4). This suggests that fibrino-
gen-mediated binding of Efb to platelets is integrin IIb3-de-
pendent, whereas Efb binding in the presence of thrombin
without exogenous fibrinogen proceeds via a different mecha-
nism and is integrin IIb3-independent. Indirectly, this sug-
gests that the levels of endogenous fibrinogen released by
washed platelets upon thrombin stimulation are significantly
lower than 3 mg/ml, the exogenous fibrinogen concentration
used in our experiments and the average concentration in plasma
(33); this is consistent with previous studies (34, 35) involving the
fibrinogen concentration released by washed platelets in vitro. In
summary, our data suggest a dualmechanism of binding of Efb by
platelets: an extracellular fibrinogen/integrin IIb3-dependent
mechanism, and a fibrinogen-independent mechanism mediated
by at least one unidentified platelet surface receptor. In addition,
FIGURE 6. P-selectin (P-sel) is responsible for Efb and fibrinogen binding by thrombin-stimulated platelets. A, FITC-labeled FGN binding by
platelets (107 ml1) in resting or thrombin- (Thr) stimulated (0.25 unit/ml) states was measured in the presence of 50 g/ml P-selectin-Fc and/or 50
g/ml integrin IIb3 inhibitory anti-CD41 antibody (CD41 Ab). B, FITC-labeled Efb was incubated at 1 M concentration on human platelets (10
7
platelets/ml) in resting (control (CTRL)) or thrombin-stimulated (0.25 units/ml) conditions. Where indicated, 50 g/ml P-selectin-Fc and/or 50 g/ml
integrin IIb3 inhibitory anti-CD41 antibody (CD41 Ab) were added to the platelet suspension, and Efb binding was assessed by flow cytometry using
a FACSAria III (n 4). Representative FITC-labeling histograms are shown in the right panelswith the percentage of events above 1000 rfu (indicated as
R1). Mean fluorescence value S.E. from four independent experiments is reported in left panels. Statistical significance was tested by one-way ANOVA
with Bonferroni post test (*  p  0.01, n  4).
Efb Blocks Interaction between P-selectin and PSGL-1
FEBRUARY 5, 2016•VOLUME 291•NUMBER 6 JOURNAL OF BIOLOGICAL CHEMISTRY 2769
 at U
N
IV
 O
F EX
ETER on N
ovem
ber 17, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
the fibrinogen-dependent binding of Efb to platelets appeared to
depend on basal levels of platelet activation in the washed platelet
preparations, because it was completely abolished by treatment
with PGE1 (Fig. 4, E and F).
Identification of Novel Efb-binding platelet Proteins—We
therefore decided to identify platelet proteins that interact with
Efb using a proteomics approach. Pulldown experiments were
performed using platelet lysates obtained by ultrasonication
and His-Select HF resin conjugated to full-length Efb in the
presence of 3 mg/ml added fibrinogen. Captured proteins were
identified bymass spectrometry (a full list of proteomics results
is shown in supplemental Table 1). Platelet surface/extracellu-
lar proteins preferentially captured by Efb-loaded resin in at
least three out of four samples were selected using a minimum
threshold ratio of pulldown peptide number to negative control
of 1.40 and are shown in Table 1. In addition to known interac-
tors of Efb (i.e. fibrinogen, complement C3, and plasminogen)
(6, 13, 16), this analysis revealed novel potential partners of Efb,
including functionally relevant proteins such as P-selectin (a
platelet plasma membrane protein) and multimerin-1, emi-
lin-1, fibronectin, and thrombospondin-1 (soluble extracellular
proteins able to interact with cell adhesion receptors on
platelets).
Proteins identified by proteomics and characterized by
expression on platelet surface or in human plasma were inves-
tigated further. Efb/Efb-N-interacting proteins were captured
from platelet lysates (obtained by ultrasonication) using Efb/
Efb-N-loaded His-Select HF resin and confirmed by immuno-
blot with specific antibodies (Fig. 5A). Integrin IIb, fibronec-
tin, multimerin-1, thrombospondin-1, and P-selectin were
confirmed to interact with Efb and Efb-N in the presence
of added extracellular fibrinogen. Interestingly, P-selectin
appeared to bind Efb and Efb-N efficiently in the absence of
added fibrinogen, whereas multimerin-1 showed some Efb
binding activity without added fibrinogen, which was potenti-
ated by adding fibrinogen. All other tested proteins depended
on the addition of exogenous fibrinogen to bind Efb/Efb-N,
suggesting that their interaction with Efb/Efb-N is fibrinogen-
mediated rather than direct. The use of full-length Efb or Efb-N
meant that these pulldown assays provided insight on the loca-
tion of the interacting domain in Efb (the proteomics data set
was obtained using full-length Efb only). For all tested proteins,
the interaction with Efb-N was at least as effective as the inter-
action with full-length Efb, suggesting that Efb-N contains the
binding site(s) for Efb interaction with its newly identified part-
ners P-selectin, multimerin-1, fibronectin, and thrombospon-
din-1. Direct interaction of Efb with P-selectin was confirmed
by SPR, revealing a Kd for Efb-P-selectin interaction in the nM
range (Fig. 5B).
Next, we tested whether P-selectin binding by Efb can par-
ticipate in the increased binding of fibrinogen by thrombin-
stimulated platelets shown in Fig. 2C. To obtain this informa-
tion, we performed FITC-fibrinogen binding experiments in
the presence of Efb and selective competitors of platelet P-se-
lectin (i.e. soluble P-selectin-Fc fusion protein) and integrin
IIb3 (i.e. inhibitory anti-CD41 antibody). These experiments
showed that P-selectin is responsible for most of the binding
of fibrinogen by activated platelets in the presence of Efb
(Fig. 6A). We then confirmed that P-selectin mediates the
interaction of Efb with platelets in the absence of fibrinogen
by assessing the binding of FITC-Efb by thrombin-stimu-
lated platelets in the presence of an excess of recombinant
P-selectin-Fc (i.e. binding competition) (Fig. 6B). As shown
above (Fig. 3), stimulation by thrombin is necessary to pro-
mote P-selectin-dependent binding of Efb by platelets. In
addition, here we show that the presence of P-selectin-Fc
fusion protein abolishes the binding of Efb by platelets.
Taken together, these data suggest that the translocation and
exposure of P-selectin on the platelet surface in response to
thrombin (36) are necessary for Efb binding by platelets in
the absence of exogenous fibrinogen.
Efb Disrupts Platelet-Leukocyte Interaction by Blocking P-se-
lectin-PSGL-1 Interaction—We subsequently focused on the
biological role of the interaction between Efb and P-selectin.
Co-immunoprecipitation experiments were conducted using
recombinant P-selectin-Fc and PSGL-1-Fc (Fig. 7A, cell-free
assay). The results (Fig. 7), including densitometry analysis,
FIGURE 7. Efb inhibits P-selectin-PSGL-1 interaction. A, P-selectin-Fc
(106 kDa) and PSGL-1-Fc (52 kDa) weremixed in PBS 1mMCaCl2 at a final
concentration of 2 g/ml and PSGL-1 was immunoprecipitated (IP) using
10 g/ml anti-PSGL-1 antibody. Tot., total. B and C, whole platelet lysates
were immunoprecipitated using anti-PSGL-1 (B) or anti-P-selectin anti-
bodies (C). Where indicated 5M Efb or Efb-N was added (equivalent to 45
and 90 g/ml, respectively). In all cases, the immunoprecipitates were
immunoblotted for P-selectin and PSGL-1. Immunoblots shown in this
figure are representative of three independent experiments. The right
panels represent the densitometric analysis of the immunoblots. Three
independent experiments were analyzed with ImageJ for band mean
intensity (minus background intensity), which is shown as average S.E.
(arbitrary units). Statistical significance was assessed by one-way ANOVA
with Bonferroni post test (*, p  0.05, n  3).
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FIGURE 8. Efb and Efb-N inhibit formation of platelet-granulocyte complexes. Leukocytes fromhuman bloodwere analyzed by flow cytometry (FACSAria III). A,
forward scattering (FSC)/side scattering (SSC) dot plot identifies three distinct subpopulations. These populations were characterized as CD66high cells (5000 rfu in
our experimental conditions), corresponding to granulocytes, and CD66low cells, further divisible into CD38 and CD38. B, distribution of CD66 expression in the
three subpopulationsof leukocytes.Dotplots for theco-staining forCD66 (granulocytes) andCD42b (platelets) foruntreated, 5MEfb-treated, 5MEfb-N-treated,or
5MEfb-C-treatedwholebloodareshown inC,D,E, andF, respectively.G, CD66/CD42bhistogramforwholebloodtreatedwithboth50g/mlP-selectin-Fcand5M
Efb. InquadrantQ2of thedotplots, thepercentageof eventswithCD66 staining5000 rfu andCD42b staining500 rfu is represented.H, theportionof leukocytes
positive for CD66 and CD42b staining (i.e. granulocyte-platelet complexes) for all tested conditions. Mean fluorescence value S.E. from four independent experi-
ments is reported. Statistical significancewas tested by one-way ANOVAwith Bonferroni post test (* p 0.01 comparedwith vehicle,NS non-significant in the
pairwise comparison between Efb or Efb-N alone and treatedwith P-selectin or P-selectin and Efb, n 4).
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demonstrate that both full-length Efb and Efb-N disrupt the
interaction between P-selectin and its endogenous ligand
PSGL-1. (Fig. 7A). This was confirmed using platelet lysates as a
source of native P-selectin and PSGL-1 (Fig. 7, B and C).
We next assessed whether Efb inhibition of P-selectin bind-
ing activity had any effect on the formation of platelet-leuko-
cyte complexes that are induced by trans-cellular interaction of
P-selectin andPSGL-1 (22, 23). As described previously (37), we
investigated basal levels of platelet-leukocyte complexes in
human whole blood by flow cytometry without additional in
vitro platelet stimulation. CD42b (also known as glycopro-
tein 1b) was utilized as a specific marker for platelets. The
leukocyte population comprised CD66high cells (5000 rfu
in our experimental conditions), corresponding to granulo-
cytes, and CD66low cells (Fig. 8, A and B). In these experi-
ments, blood particles characterized by high levels of CD66
and CD42b markers are complexes between granulocytes
and platelets (Fig. 8C). Remarkably, blood incubation with 5
M Efb or Efb-N significantly reduced the presence of gran-
ulocyte-platelet complexes, whereas 5 M Efb-C did not
affect granulocyte-platelet complex concentration (Fig. 8,
D--F). In addition, we found that the addition of 50 g/ml
P-selectin-Fc significantly reduced platelet-granulocyte
complexes when added alone (data not shown) but did not
have any additive effect when added with Efb (Fig. 8G).
Quantification of these results is shown in Fig. 8H.
Non-granulocyte leukocytes (CD66low) are further divisible
into lymphocytes andmonocytes. Lymphocytes andmonocytes
were distinguished using CD38 as a monocyte marker (i.e.
CD66low/CD38 cells are monocytes, whereas CD66low/
CD38 cells are lymphocytes) (Fig. 9,A and B).We focused our
attention on monocytes (CD38). Blood particles positive for
CD42b and CD38 within this population (CD66low/CD38/
CD42b) are complexes betweenmonocytes and platelets (Fig.
9C); these complexes were also decreased by incubation with 5
M Efb or Efb-N (Fig. 9,D and E), but not Efb-C (Fig. 9F). Also,
50g/ml P-selectin-Fc significantly reducedplatelet-monocyte
complexes when added alone (data not shown) but did not have
any additive effect when added with Efb (Fig. 9G). Quantifica-
tion of these results is shown in Fig. 9H.
Discussion
Similar to other proteins produced and released by S. aureus,
including coagulase (Coa), extracellularmatrix-binding protein
(Emp), extracellular adhesive protein (Eap), staphylococcal
complement inhibitor (SCIN), Sbi, and chemotaxis inhibitory
protein (CHIPS) (3–5), Efb has attracted attention due to its
role in the progression of S. aureus infection. Previous studies
have highlighted the ability of Efb to inhibit platelet activa-
tion and hemostasis (18, 19). In addition, Efb has been shown
to facilitate the escape of S. aureus from phagocytosis (15),
exacerbate S. aureus infections (16, 20), and impair wound
healing (17). The immunosuppressant role of Efb has been
linked to its ability to interfere with the complement system
and reduce bacterial phagocytosis (13, 15). The antihemo-
static activity of Efb, however, has been suggested to depend
on inhibition of fibrinogen binding by platelets or inhibition
of platelet activation in response to fibrinogen binding,
although the mechanism has not been resolved (18, 19). We
therefore investigated the nature of Efb-platelet interaction
at the molecular level.
In our thrombus formation and aggregation experiments, we
localized the antiplatelet activity of Efb to its N-terminal
domain, Efb-N (Fig. 1). This is in accordance with our binding
experiments showing that full-length Efb and Efb-N bind the
surface of platelets in the presence of thrombin or fibrinogen,
whereas Efb-C does not (Fig. 3). This is also in accordance with
previous studies showing antithrombotic activity of Efb N-ter-
minal domain constructs (19). Our observations of Efb promo-
tion of FITC-fibrinogen binding to platelets (Fig. 2), although
initially unexpected, are in agreement with previous studies
showing the promotion rather than inhibition of fibrinogen
binding by platelets in the presence of Efb (18, 21); interestingly,
these studies concluded that “enhanced Efb-dependent fibrin-
ogen binding to platelets is of a nature that does not promote
aggregation of the platelets” (i.e. “a non-functional interaction
between platelets and fibrinogen”).
Our experiments with or without added extracellular fibrin-
ogen have clarified the nature of Efb-platelet interaction and
the role of fibrinogen, showing that there are two independent
Efb-platelet binding modes: a fibrinogen-dependent binding
modemediated by integrinIIb3 (Fig. 4D) (which occurs in the
presence of high extracellular concentrations of fibrinogen),
and a novel platelet activation-dependent binding mode medi-
ated by P-selectin but independent of fibrinogen (Fig. 6B)
(which occurs in the absence of high extracellular concentra-
tions of fibrinogen). This conclusion was reached in experi-
ments on washed platelets; previous studies highlighted that
the concentration of fibrinogen (100 g/ml) released by
washed platelets in vitro (34, 35) is at least an order of magni-
tude lower than the average plasma concentration of fibrinogen
in healthy blood donors of	3mg/ml (33). Interestingly, several
platelet functional responses depend on high concentrations of
fibrinogen that cannot be attained by simple release by plate-
lets. For example, platelet aggregation in response to weak ago-
nists such as serotonin or ADP can take place only in PRP
(where high fibrinogen concentrations are found) or in washed
FIGURE 9.Efb andEfb-N inhibit formationof platelet-monocyte complexes. Leukocytes fromhumanbloodwere analyzedby flow cytometry (FACSAria III).
A, forward scattering (FSC)/side scattering (SSC) dot plot identifies three distinct subpopulations. These populations were characterized as CD66high cells
(5000 rfu in our experimental conditions), corresponding to granulocytes, and CD66low cells, further divisible into CD38 and CD38 (i.e. monocytes and
lymphocytes). B, distribution of CD38 expression in the three subpopulations of leukocytes. Within the CD66low/CD38 population, dot plots for the co-stain-
ing for CD38 (granulocytes) and CD42b (platelets) for untreated, 5M Efb-treated, 5M Efb-N-treated, or 5M Efb-C-treated whole blood are shown in C, D,
E, and F, respectively. G, CD38/CD42b histogram for CD66low/CD38 population following treatment with both 50 g/ml P-selectin-Fc and 5 M Efb. In
quadrant Q2 of the dot plots, the percentage of events with CD38 staining100 rfu and CD42b staining500 rfu is represented. H, the portion of CD66low/
CD38 leukocytes positive for CD42b staining (i.e.monocyte-platelet complexes) for all tested conditions. Mean fluorescence value S.E. from four indepen-
dent experiments is reported. Statistical significance was tested by one-way ANOVA with Bonferroni post test (*  p  0.01 compared with vehicle, NS 
non-significant in the pairwise comparison between Efb or Efb-N alone and treated with P-selectin, or P-selectin and Efb, n 4).
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platelets with added fibrinogen or plasma proteins (38). It is
therefore reasonable to assume that Efb binding to washed
platelets in the absence of exogenous fibrinogen is fibrinogen-
independent. This was confirmed by experiments using an
inhibitory antibody for the main fibrinogen receptor on plate-
lets, integrin IIb3, which showed no effect on Efb binding by
platelets in the absence of exogenous fibrinogen. On the other
hand, we proved that fibrinogen-dependent binding of Efb in
the absence of stimulation is caused by basal levels of platelet
and integrin IIb3 activation (Fig. 4, E and F).
The fibrinogen-independent binding of Efb to platelets is
mediated by a platelet surface/extracellular protein that was
previously unknown as a binding partner of Efb. Notably, the
existence of an unidentified surface receptor for Efb was sug-
gested by previous studies (18). We have now identified P-se-
lectin as the surface protein responsible formediating the inter-
action between Efb and platelets in the absence of high
extracellular fibrinogen concentration. We initially identified
P-selectin among platelet proteins as an Efb interactor using a
proteomics approach (Table 1). We then confirmed this inter-
action using classical biochemical techniques (pulldown and
immunoblot) and SPR.We showed that Efb-P-selectin interac-
tion is fibrinogen-independent and occurs via Efb-N (Fig. 5).
The translocation of platelet P-selectin to the platelet surface in
response to platelet activation has been described (36) and
explains why P-selectin-mediated binding of Efb becomes sig-
nificant only after platelet activation (induced by thrombin in
our experiments). The capability of Efb-N to bind both fibrin-
ogen and P-selectin could be related to the intrinsically disor-
dered nature of Efb-N (data not shown), noting that disorder
often confers an increased repertoire of possible interactions on
a protein domain (39).
The interaction between P-selectin and its endogenous
ligand PSGL-1 is central to the formation of platelet-leukocyte
complexes (40, 41) and the immune function of platelets (42).
We therefore investigated the ability of Efb to affect the levels of
heterotypic cell complexes between platelets and leukocytes in
human blood. Platelet-granulocyte and platelet-monocyte
complex levels were indeed significantly decreased by Efb and
Efb-N (Figs. 8 and 9). In view of the role of platelet-leukocyte
complex formation in the innate immune response (43), our
findings suggest that at least part of the immunosuppressive
role of Efb (16, 20) involves inhibition of platelet-leukocyte
complex formation. In this respect, besides offering potential
new angles to tackle S. aureus infections, understanding of the
mechanism of action of Efb may have wider consequences.
Platelet-leukocyte complexes have been shown to play an
important role in inflammation (27, 44). As well as being useful
research tools for the study of platelet-leukocyte complexes,
peptides derived from Efb-N could therefore be the basis of a
therapeutic agent for inflammatory diseases that are character-
ized by increased formation of platelet-leukocyte complexes;
such diseases include atherosclerosis (45), autoimmune dis-
eases (46, 47), and inflammatory thrombosis (48, 49). The inter-
action between P-selectin and its physiological ligand PSGL-1
has also been shown to play a critical role in the interaction of
platelets with endothelial cells and the initiation of thrombosis
(50–52). Therefore, this study may offer valuable information
for the investigation or treatment of pro-thrombotic states
induced by vascular inflammation and increased endothelial
cell-platelet adhesion.
In summary, we have demonstrated for the first time a novel
biological activity of the S. aureus protein Efb: inhibition of
P-selectin-PSGL-1 interaction and consequent impairment of
platelet-leukocyte complex formation. This function helps to
explain the pathogenic role of Efb during S. aureus infection.
Efb-based molecules may therefore be used to target the
inflammatory function of platelets, which depends on
P-selectin-dependent interaction with leukocytes.
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